Sanofi Pasteur and the Infectious Disease Research Institute establish vaccine research & development centre

Aims to accelerate time to market and decrease development costs of life-saving vaccines

Sanofi Pasteur, the vaccines division of Sanofi, has created a Global Health Vaccine Centre of Innovation (GHVCI) with the Infectious Disease Research Institute (IDRI), to be headquartered in Seattle, US. The project is funded in part by a grant from the Bill & Melinda Gates Foundation.

The GHVCI aims to accelerate the development of vaccines and supporting technologies to address infectious diseases and ensuring that these new critical vaccines are available to populations in developing countries.

The addition of IDRI will enable vaccine adjuvant/formulation platforms and a pipeline of vaccine candidates to be discovered, evaluated and developed to address a range of infectious diseases under the centre of innovation based at IDRI.

Sanofi Pasteur will leverage the resources and expertise of this external R&D innovation centre and obtain access to IDRI's adjuvants and vaccine antigens.

Funding for the establishment, operation and growth of the GHVCI will come from Sanofi and the Gates Foundation, and additional funding will be sought to support collaborative research activities with respect to specific vaccines to be developed at the GHVCI.

'There are a number of diseases that are of great global-health significance, where Sanofi Pasteur could significantly contribute,' said John Shiver, Senior VP for R&D at Sanofi Pasteur.

'The establishment of this Global Health Vaccines Centre of Innovation represents a new opportunity – operating within the open innovation R&D model – to provide antigens, adjuvanted formulations, funding, and expertise to allow development of needed vaccines.'

Companies